Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614454 · ClinicalTrials.gov registry record · Phase 2
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
A Phase 2 study of Neuromyelitis Optica, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT04614454: Completed Phase 2 study of Neuromyelitis Optica, sponsored by Massachusetts General Hospital.
NCT04614454 is a Phase 2 study of Neuromyelitis Optica that has completed, run by Massachusetts General Hospital. The registered enrollment target is 46 participants, below the 508-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04614454, a Phase 2 study of Neuromyelitis Optica, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients with Neuromyelitis optica spectrum disorder (NMOSD).
Primary Outcome
The NRS scale is an 11 point scale (0-10) with 0 as no pain and 10 as worst pain to determine the pain level. The result posted here is difference between the NRS at baseline and the NRS at 4 weeks.
Conditions Studied
Interventions
- DEVICE High Frequency Impulse Therapy
- DEVICE High Frequency Impulse Therapy - Sham
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 2 |
What the finished NCT04614454 record still lists
NCT04614454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 508-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Neuromyelitis Optica appearing as the primary indexed condition, and to 2 interventions - of which High Frequency Impulse Therapy is the first listed.
NCT04614454 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04614454 about?
NCT04614454 is a clinical study titled "High Frequency Impulse Therapy for Neuropathic Pain in NMOSD". The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients with Neuromyelitis optica spectrum disorder (NMOSD).
What is the current status of trial NCT04614454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2021-06-07. Estimated completion is 2025-01-15.
What conditions does trial NCT04614454 study?
This clinical trial studies the following conditions: Neuromyelitis Optica.
What interventions are being tested in trial NCT04614454?
The interventions under investigation include: High Frequency Impulse Therapy (DEVICE), High Frequency Impulse Therapy - Sham (DEVICE).
Who is sponsoring clinical trial NCT04614454?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04614454 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
RECRUITING
-
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
RECRUITING · NA
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
COMPLETED · Phase 4
-
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI